Novel lymphotoxin alpha (LTalpha) knockout mice with unperturbed tumor necrosis factor expression: reassessing LTalpha biological functions. 2006

Dmitry J Liepinsh, and Sergei I Grivennikov, and Kimberly D Klarmann, and Maria A Lagarkova, and Marina S Drutskaya, and Stephen J Lockett, and Lino Tessarollo, and Matthew McAuliffe, and Jonathan R Keller, and Dmitry V Kuprash, and Sergei A Nedospasov
Basic Research Program, SAIC-Frederick, Inc., NCI--Frederick, Frederick, Maryland 21702, USA.

Lymphotoxin alpha (LTalpha) can exist in soluble form and exert tumor necrosis factor (TNF)-like activity through TNF receptors. Based on the phenotypes of knockout (KO) mice, the physiological functions of LTalpha and TNF are considered partly redundant, in particular, in supporting the microarchitecture of the spleen and in host defense. We exploited Cre-LoxP technology to generate a novel neomycin resistance gene (neo) cassette-free LTalpha-deficient mouse strain (neo-free LTalpha KO [LTalphaDelta/Delta]). Unlike the "conventional" LTalpha-/- mice, new LTalphaDelta/Delta animals were capable of producing normal levels of systemic TNF upon lipopolysaccharide (LPS) challenge and were susceptible to LPS/D-galactosamine (D-GalN) toxicity. Activated neutrophils, monocytes, and macrophages from LTalphaDelta/Delta mice expressed TNF normally at both the mRNA and protein levels as opposed to conventional LTalpha KO mice, which showed substantial decreases in TNF. Additionally, the spleens of the neo-free LTalpha KO mice displayed several features resembling those of LTbeta KO mice rather than conventional LTalpha KO animals. The phenotype of the new LTalphaDelta/Delta mice indicates that LTalpha plays a smaller role in lymphoid organ maintenance than previously thought and has no direct role in the regulation of TNF expression.

UI MeSH Term Description Entries
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008221 Lymphoid Tissue Specialized tissues that are components of the lymphatic system. They provide fixed locations within the body where a variety of LYMPHOCYTES can form, mature and multiply. The lymphoid tissues are connected by a network of LYMPHATIC VESSELS. Lymphatic Tissue,Lymphatic Tissues,Lymphoid Tissues,Tissue, Lymphatic,Tissue, Lymphoid,Tissues, Lymphatic,Tissues, Lymphoid
D008233 Lymphotoxin-alpha A tumor necrosis factor family member that is released by activated LYMPHOCYTES. Soluble lymphotoxin is specific for TUMOR NECROSIS FACTOR RECEPTOR TYPE I; TUMOR NECROSIS FACTOR RECEPTOR TYPE II; and TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14. Lymphotoxin-alpha can form a membrane-bound heterodimer with LYMPHOTOXIN-BETA that has specificity for the LYMPHOTOXIN BETA RECEPTOR. TNF Superfamily, Member 1,TNF-beta,Tumor Necrosis Factor Ligand Superfamily Member 1,Tumor Necrosis Factor-beta,Lymphotoxin,Lymphotoxin-alpha3,Soluble Lymphotoxin-alpha,alpha-Lymphotoxin,Lymphotoxin alpha,Lymphotoxin alpha3,Lymphotoxin-alpha, Soluble,Soluble Lymphotoxin alpha,Tumor Necrosis Factor beta,alpha Lymphotoxin
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009355 Neomycin Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis. Fradiomycin Sulfate,Neomycin Palmitate,Neomycin Sulfate
D010047 Ovalbumin An albumin obtained from the white of eggs. It is a member of the serpin superfamily. Serpin B14
D005620 Freund's Adjuvant An antigen solution emulsified in mineral oil. The complete form is made up of killed, dried mycobacteria, usually M. tuberculosis, suspended in the oil phase. It is effective in stimulating cell-mediated immunity (IMMUNITY, CELLULAR) and potentiates the production of certain IMMUNOGLOBULINS in some animals. The incomplete form does not contain mycobacteria. Freund Adjuvant,Adjuvant, Freund,Adjuvant, Freund's,Freunds Adjuvant
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody

Related Publications

Dmitry J Liepinsh, and Sergei I Grivennikov, and Kimberly D Klarmann, and Maria A Lagarkova, and Marina S Drutskaya, and Stephen J Lockett, and Lino Tessarollo, and Matthew McAuliffe, and Jonathan R Keller, and Dmitry V Kuprash, and Sergei A Nedospasov
April 1998, Hepatology (Baltimore, Md.),
Dmitry J Liepinsh, and Sergei I Grivennikov, and Kimberly D Klarmann, and Maria A Lagarkova, and Marina S Drutskaya, and Stephen J Lockett, and Lino Tessarollo, and Matthew McAuliffe, and Jonathan R Keller, and Dmitry V Kuprash, and Sergei A Nedospasov
August 1998, The Journal of experimental medicine,
Dmitry J Liepinsh, and Sergei I Grivennikov, and Kimberly D Klarmann, and Maria A Lagarkova, and Marina S Drutskaya, and Stephen J Lockett, and Lino Tessarollo, and Matthew McAuliffe, and Jonathan R Keller, and Dmitry V Kuprash, and Sergei A Nedospasov
March 2001, Cytokine & growth factor reviews,
Dmitry J Liepinsh, and Sergei I Grivennikov, and Kimberly D Klarmann, and Maria A Lagarkova, and Marina S Drutskaya, and Stephen J Lockett, and Lino Tessarollo, and Matthew McAuliffe, and Jonathan R Keller, and Dmitry V Kuprash, and Sergei A Nedospasov
July 2000, European journal of immunology,
Dmitry J Liepinsh, and Sergei I Grivennikov, and Kimberly D Klarmann, and Maria A Lagarkova, and Marina S Drutskaya, and Stephen J Lockett, and Lino Tessarollo, and Matthew McAuliffe, and Jonathan R Keller, and Dmitry V Kuprash, and Sergei A Nedospasov
November 2008, The Journal of steroid biochemistry and molecular biology,
Dmitry J Liepinsh, and Sergei I Grivennikov, and Kimberly D Klarmann, and Maria A Lagarkova, and Marina S Drutskaya, and Stephen J Lockett, and Lino Tessarollo, and Matthew McAuliffe, and Jonathan R Keller, and Dmitry V Kuprash, and Sergei A Nedospasov
April 2002, The Journal of biological chemistry,
Dmitry J Liepinsh, and Sergei I Grivennikov, and Kimberly D Klarmann, and Maria A Lagarkova, and Marina S Drutskaya, and Stephen J Lockett, and Lino Tessarollo, and Matthew McAuliffe, and Jonathan R Keller, and Dmitry V Kuprash, and Sergei A Nedospasov
April 1997, European journal of immunology,
Dmitry J Liepinsh, and Sergei I Grivennikov, and Kimberly D Klarmann, and Maria A Lagarkova, and Marina S Drutskaya, and Stephen J Lockett, and Lino Tessarollo, and Matthew McAuliffe, and Jonathan R Keller, and Dmitry V Kuprash, and Sergei A Nedospasov
January 1996, International immunology,
Dmitry J Liepinsh, and Sergei I Grivennikov, and Kimberly D Klarmann, and Maria A Lagarkova, and Marina S Drutskaya, and Stephen J Lockett, and Lino Tessarollo, and Matthew McAuliffe, and Jonathan R Keller, and Dmitry V Kuprash, and Sergei A Nedospasov
June 1992, Current opinion in immunology,
Dmitry J Liepinsh, and Sergei I Grivennikov, and Kimberly D Klarmann, and Maria A Lagarkova, and Marina S Drutskaya, and Stephen J Lockett, and Lino Tessarollo, and Matthew McAuliffe, and Jonathan R Keller, and Dmitry V Kuprash, and Sergei A Nedospasov
January 2000, Gene,
Copied contents to your clipboard!